NHS saved £324 million by switching to biosimilars and generics
Lupin’s biosimilar is under review in EU
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Mylan takes aim at Allergan’s off-patent blockbuster
Big-selling Humalog facing cut price competition
Mylan and Biocon resolve biosimilar manufacturing issues